Patents Examined by Kristin A Vajda
  • Metalloenzyme inhibitor compounds
    Patent number: 11136309
    Abstract: Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: October 5, 2021
    Assignee: PHASEBIO PHARMACEUTICALS, INC.
    Inventors: Steven Sparks, Christopher M. Yates, Sammy R. Shaver
  • Sulfonylureas and related compounds and use of same
    Patent number: 11130731
    Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: September 28, 2021
    Assignees: The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The University Of Queensland
    Inventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder
  • Compounds inhibiting Nef-calnexin interaction
    Patent number: 11131661
    Abstract: The invention relates to compounds and methods for restoring or preserving cholesterol efflux in a cell infected with Human Immunodeficiency Virus (HIV) by preventing or decreasing an interaction between Negative Regulatory Factor (Nef) protein and Calnexin protein, and methods for screening for such compounds.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: September 28, 2021
    Assignee: THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION
    Inventors: Alexei Adzhubei, Michael Bukrinsky, Ruth Hunegnaw
  • Prodrugs of Naltrexone, Nalmefene and derivatives thereof
    Patent number: 11130771
    Abstract: A novel structure of an opioid antagonist is provided. One of the exemplary compounds of the present disclosure has the structure of Formula (II). The present disclosure overcomes the discomfort of conventional opioid antagonist due to rapid absorption and improves the patient compliance thereof.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: September 28, 2021
    Assignee: TAIWANJ PHARMACEUTICALS CO., LTD.
    Inventors: Syaulan S. Yang, Kuang Yuan Lee, Yan-Feng Jiang
  • Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors
    Patent number: 11130751
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: September 28, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick René Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry François Alain Jean Jousseaume
  • 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof
    Patent number: 11117877
    Abstract: Compounds of formula (II) are provided for stabilizing protein transthyretin (TTR) and inhibiting amyloid fibril formation, for example, transthyretin-mediated amyloid fibril formation, and for treating, preventing, or ameliorating one or more symptoms of amyloid diseases, for example, transthyretin-related amyloidosis (ATTR).
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: September 14, 2021
    Assignee: BSIM Therapeutics, S.A.
    Inventors: Rui Manuel Pontes Meireles Ferreira de Brito, Carlos José Vieira Simões, Teresa Margarida Vasconcelos Dias de Pinho e Melo, Bruno Lourenço da Silva Victor, Zaida Catarina Lourenço de Almeida, Ana Lúcia Cabral Cardoso Lopes, Bruno Filipe Oliveira Nascimento
  • Compositions and methods for the delivery of therapeutics
    Patent number: 11117904
    Abstract: The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: September 14, 2021
    Assignees: ViiV Healthcare Company, Board of Regents of University of Nebraska
    Inventors: Benson J. Edagwa, Howard E. Gendelman, Brian Alvin Johns
  • Voltage gated sodium channel imaging agents
    Patent number: 11117858
    Abstract: Provided herein are radiolabeled compounds useful for minimally invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for position emission tomography imaging of voltage gated sodium channels. Methods for prepared unlabeled and labeled compounds, and diagnostic methods using the compounds are also provided.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: September 14, 2021
    Assignee: The General Hospital Corporation
    Inventors: Matthias Schoenberger, Jacob Hooker
  • Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
    Patent number: 11098010
    Abstract: The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 24, 2021
    Assignee: Arbutus Biopharma Corporation
    Inventors: Andrew G. Cole, Bruce D. Dorsey, Ramesh Kakarla, Steven Kultgen, Jorge Quintero
  • Organic electroluminescent materials and devices
    Patent number: 11098245
    Abstract: Novel Iridium complexes having three different bidentate ligands useful for phosphorescent emitters in OLEDs are disclosed. At least one of the three different bidentate ligands is a carbene ligand.
    Type: Grant
    Filed: September 7, 2019
    Date of Patent: August 24, 2021
    Assignee: UNIVERSAL DISPLAY CORPORATION
    Inventors: Jui-Yi Tsai, Chuanjun Xia, Chun Lin, Adrian U. Palacios, Enrique Oñate, Miguel A. Esteruelas, Pierre-Luc T. Boudreault, Sonia Bajo, Montserrat Oliván
  • Adducts of pyrrole derivatives to carbon allotropes
    Patent number: 11098012
    Abstract: Adducts are described formed between pyrrole derivatives of formula (I) an carbon allotropes in which the carbon is sp2 hybridized, such as for example carbon nanotubes, graphene or nanographites, carbon black. The pyrrole derivatives bear substituents on the nitrogen atom suitable for improving the physicochemical characteristics of said allotropes. A process for preparing said adducts is also described. The adducts are formed with a pyrrole of formula (I) wherein X is selected from the group consisting of: The other substituents are as defined in the claims.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: August 24, 2021
    Assignee: PIRELLI TYRE S.p.A.
    Inventors: Maurizio Stefano Galimberti, Vincenzina Barbera
  • Composition for preventing or treating muscle diseases, comprising suberic acid or pharmaceutically acceptable salt thereof as active ingredient
    Patent number: 11096917
    Abstract: The present invention relates to a composition for preventing or treating a muscular disease or improving muscle function. The composition includes suberic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: August 24, 2021
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventor: Tae Sun Park
  • Therapeutic heterocyclic compounds
    Patent number: 11098027
    Abstract: Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 24, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Elfatih Elzein, Xiaofen Li
  • Compounds and compositions for inducing chondrogenesis
    Patent number: 11091499
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating joint damage or injury in a mammal, for inducing hyaline cartilage production or for inducing differentiation of chondrogenic progenitor cells into mature chondrocytes.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: August 17, 2021
    Assignee: Novartis AG
    Inventors: Ha-Soon Choi, Jiqing Jiang, James Paul Lajiness, Bao Nguyen, Hank Michael James Petrassi
  • Aminophosphinic derivatives for preventing and treating eye inflammation
    Patent number: 11090317
    Abstract: The disclosure relates to compounds of formula (I): R1-NH—CH(R2)-P(?O)(OH)—CH2-C(R3)(R4)-CONH—C(R5)(R6)-COOR7, where R1 to R7 are as defined in the claims, for use of same in the treatment and/or prevention of ocular inflammation, and more particularly for improving the process of ocular healing. Thus, the compounds of formula (I) are used, in particular, to prevent neovascularisation, or to prevent or treat an ocular inflammation linked to a keratitis, scleritis, episcleritis, uveitis, cataract, synechia, macular oedema, detachment of the retina, ocular hypertension and degeneration of the optical nerve caused by glaucoma.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: August 17, 2021
    Assignee: Pharmaleads
    Inventors: Hervé Poras, Michel Wurm, Stéphane Melik Parsadaniantz, Annabelle Reaux-Le Goazigo
  • Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
    Patent number: 11084800
    Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: August 10, 2021
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang, Joel Charles Barrish, William Greenlee, Kyle J. Eastman
  • Compositions of cyclin dependent kinase 7 (CDK7) inhibitor
    Patent number: 11083728
    Abstract: The present invention provides, in part, compositions comprising an inhibitor of cyclin-dependent kinase 7 (CDK7) and sulfobutyl ether-?-cyclodextrin. Also provided are methods of using a disclosed composition for treating proliferative diseases. The present invention also provides methods of making disclosed compositions.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: August 10, 2021
    Assignee: Syros Pharmaceuticals, Inc.
    Inventor: Neera Jain
  • Pharmaceutical compounds
    Patent number: 11078189
    Abstract: Benzimidazole derivatives of formula (I): wherein: R1 is —(CH2)m-R4 or R2 is halo, —(CH2)m—NH2 or —(CH2)n—C(?NH)—NH2; R3 is H or F; R4 is —NH—(CH2)2—(NH)r—R5, —NH—(CHR5R6) or a group of the following formula (A): (A) W is —(CH2)m—, —CH2—O—CH2—, —CH2—S—CH2—, —(CH2)r—S(O)2—CH2— or —(CH2)r—NR5—CH2—; m is an integer of 1 to 3; n is 1 or 2; p is 1 and V is CH; or p is O and V is N; q is 0 or 1; r is 0 or 1; R5 is H, —SO2Me, —SO2Et, —SO2CF3, —COMe, —CONMe2, —CONH2 or —CH2CH2SO2Me; R6 is H or C1-C6 alkyl; and R7 is —SO2Me, —SO2Et, —SO2CF3, —COMe, —CONMe2, —CONH2 or —CH2CH2SO2Me; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: August 3, 2021
    Assignee: REVIRAL LIMITED
    Inventors: Stuart George Cockerill, James Good
  • Therapy for mitochondrial fatty acid beta-oxidation and transport disorders
    Patent number: 11077105
    Abstract: Methods of treating mitochondrial fatty acid b-oxidation and/or transport disorders arising from mutant proteins in the mitochondrial fatty acid ?-oxidation and transport metabolic pathways in patients are provided. The methods modulate the mitochondrial fatty acid ?-oxidation pathway at the last step so that the product of the mutant protein accumulates and stabilizes the mutant protein and/or the substrate(s)/product(s) of the down stream reactions accumulate and possibly bind to allosteric sites on the mutant protein to stabilize it. Trimetazidine pharmacodynamics function as such in the ?-oxidation pathway. Further, a synergistic effect is observed where trimetazidine and PPAR? agonist combination enhanced enzyme activity and presence significantly more than either alone.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: August 3, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Al-Walid A. Mohsen, Gerard Vockley
  • Opioid receptor ligands and methods of using and making same
    Patent number: 11077098
    Abstract: This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: August 3, 2021
    Assignee: Trevena, Inc.
    Inventors: Dennis Yamashita, Dimitar Gotchev, Philip Pitis, Xiao-Tao Chen, Guodong Liu, Catherine C. K. Yuan